NSW Health Update on Medication Prescribing and Shortages

NSW Health has provided an update on GP medication prescribing in relation to the psychiatry workforce disruption, which is expected to continue until at least early June.

Medication Prescribing

Some medications for managing mental health or developmental disorders require either prescribing by psychiatrists or psychiatrist-led co-management arrangements with GPs.

SafeScript NSW can be used to apply for and manage approvals to prescribe or supply:

• Methadone and buprenorphine under the NSW Opioid Treatment Program (OTP)
• Psychostimulants (dexamphetamine, lisdexamfetamine, methylphenidate)
• Schedule 8 medicines for pain management
• Schedule 8 benzodiazepines (alprazolam, flunitrazepam)
• Ketamine and esketamine for treatment-resistant depression

These changes allow GPs to apply for interim approval to continue treatment for patients whose medication was initiated in public health facilities, without requiring a co-management arrangement to be in place. For the latest prescribing requirements and updates, visit the NSW Health News and Notices webpage.

Medication Shortage

A global shortage of methylphenidate modified-release tablets (Concerta and Methylphenidate-Teva) is affecting availability. NSW Health has introduced a temporary exemption to help patients access their medication. Until 30 June 2025, pharmacists can return prescriptions to patients so they can take them to another pharmacy with stock. This exemption may be extended if needed. Please share this update with patients to help ensure continued access to their medication.

Support Available for GPs

• Our GP Psychiatry Support Line continues to provide GPs with free psychiatry advice to help manage the care of patients.
• The Telepsychiatry Service provides eligible patients with free telehealth psychiatry consultations through a GP referral.